<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03471351</url>
  </required_header>
  <id_info>
    <org_study_id>RP6530+Pembrolizumab-1701</org_study_id>
    <nct_id>NCT03471351</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Tenalisib (RP6530) in Combination With Pembrolizumab in Relapsed or Refractory cHL</brief_title>
  <official_title>An Open Label, Phase I/II Study to Evaluate the Safety and Efficacy of RP6530, a Novel PI3K δ/γ Dual Inhibitor Given in Combination With an Anti-PD-1 Therapy, Pembrolizumab in Adult Patients With Relapsed or Refractory cHL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rhizen Pharmaceuticals SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rhizen Pharmaceuticals SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To characterize safety, tolerability and to establish the maximum tolerated dose (MTD) for&#xD;
      Tenalisib in combination with Pembrolizumab in patients with cHL.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    At this point, the current study in HL does not fit into clinical development and regulatory&#xD;
    strategy.&#xD;
  </why_stopped>
  <start_date type="Actual">July 18, 2018</start_date>
  <completion_date type="Actual">February 13, 2019</completion_date>
  <primary_completion_date type="Actual">February 13, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) for Tenalisib in combination with Pembrolizumab in patients with cHL</measure>
    <time_frame>21 days</time_frame>
    <description>The MTD was defined as the highest dose level at which no more than 1 in 6 participants experienced a dose-limiting toxicity (DLT) during the first 21-day cycle of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax)</measure>
    <time_frame>21 days</time_frame>
    <description>Assessment of Cmax in subjects treated with RP6530 and pembrolizumab combination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR) with Tenalisib and Pembrolizumab combination</measure>
    <time_frame>12 weeks</time_frame>
    <description>No of patients with partial and complete response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR) with Tenalisib and Pembrolizumab combination</measure>
    <time_frame>12 weeks</time_frame>
    <description>The time period from the response achieved in patient until the disease progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS) with Tenalisib and Pembrolizumab combination</measure>
    <time_frame>12 weeks</time_frame>
    <description>Progression-free survival was defined as the time from enrollment in the study to disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conversion Rate with Tenalisib and Pembrolizumab combination</measure>
    <time_frame>12 weeks</time_frame>
    <description>Defined as improved outcome status (i.e Improve from PR to CR or from SD to PR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving CR and PR with Tenalisib and Pembrolizumab combination</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Classical Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Tenalisib+Pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive Tenalisib in escalating doses Orally BID and pembrolizumab as a fixed dose intravenously (IV) in Escalation and Expansion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenalisib</intervention_name>
    <description>Tenalisib, BID, orally and Pembrolizumab 200 mg IV Q3W</description>
    <arm_group_label>Tenalisib+Pembrolizumab</arm_group_label>
    <other_name>RP6530</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Tenalisib, BID, orally and Pembrolizumab 200 mg IV Q3W</description>
    <arm_group_label>Tenalisib+Pembrolizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 years on the day of signing informed consent.&#xD;
&#xD;
          2. Histologically confirmed diagnosis of cHL.&#xD;
&#xD;
          3. Disease status as defined as.&#xD;
&#xD;
               -  Refractory patients who are naïve to anti-PD-1/PDL-1 therapy OR Relapsed after 3&#xD;
                  or more lines of therapies; and are naïve to anti-PD-1/PDL-1 therapy OR&#xD;
&#xD;
               -  Patients currently on Pembrolizumab and achieve a less than complete response&#xD;
&#xD;
          4. Must have ECOG performance status of 0 or 1&#xD;
&#xD;
          5. At least one bi-dimensional measurable lesion with minimum measurement of &gt; 15 mm in&#xD;
             the longest diameter.&#xD;
&#xD;
          6. Toxicities related to prior therapy must have returned to Grade 1 or less, except for&#xD;
             alopecia.&#xD;
&#xD;
               1. Adequate bone marrows, liver and renal function as assessed by the following&#xD;
                  laboratory requirements. Hemoglobin ≥8.0 g/dL (may not be transfused or treated&#xD;
                  with erythropoietin in preceding week to maintain or exceed this level)&#xD;
&#xD;
               2. Absolute neutrophil count (ANC) ≥1,000/µL&#xD;
&#xD;
               3. Platelet count ≥75,000/μL&#xD;
&#xD;
               4. Total bilirubin ≤1.5 times the ULN (or ≤3 x ULN, if patient has Gilbert syndrome)&#xD;
&#xD;
               5. ALT and AST ≤2.5 x ULN&#xD;
&#xD;
               6. Serum creatinine ≤ 1.5 x ULN or CrCl &gt; 60 ml/min (Cockcroft-Gault formula)&#xD;
&#xD;
          7. Use of an effective means of contraception for women of childbearing potential and men&#xD;
             with partners of childbearing potential&#xD;
&#xD;
          8. Provide written informed consent prior to any study-specific screening procedures.&#xD;
&#xD;
          9. Willingness and capability to comply with the requirements of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient receiving anticancer therapy (e.g. chemotherapy, biologic therapy, hormonal&#xD;
             therapy, surgery and/or tumor embolization) ≤3 weeks or 5 half-lives (whichever is&#xD;
             shorter) prior to C1D1,&#xD;
&#xD;
          2. Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137 or anti CTLA-4&#xD;
             antibody or any other antibody or drug specifically targeting T-cell co-stimulation or&#xD;
             checkpoint pathways)&#xD;
&#xD;
          3. Radiotherapy within the last 21 days prior to C1D1 (limited field palliative radiation&#xD;
             is allowed if ≥ 14 days prior to C1D1);&#xD;
&#xD;
          4. Investigational drug therapy outside of this trial during or within 3 weeks prior to&#xD;
             C1D1.&#xD;
&#xD;
          5. Patients with Allo-SCT on active GVHD or immunosuppression therapy within 3 months&#xD;
             prior to C1D1.&#xD;
&#xD;
          6. Patient with active autoimmune disease or any medical condition requiring the use of&#xD;
             systemic immunosuppressive medications .&#xD;
&#xD;
          7. Pregnancy or lactation.&#xD;
&#xD;
          8. Known clinically active CNS involvement.&#xD;
&#xD;
          9. Evidence of active Hepatitis B, active Hepatitis C infection (HCV) or cytomegalovirus&#xD;
             (CMV) or known history of HIV.&#xD;
&#xD;
         10. Subjects with concomitant second malignancies&#xD;
&#xD;
         11. Patient with any active immune toxicity of Grade 1 or greater or any other severe or&#xD;
             Grade 3 treatment-related adverse event.&#xD;
&#xD;
         12. History of Grade 4 anaphylactic reaction to monoclonal antibody therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhizen Pharmaceuticals investigational trial site; Karmanos Cancer Institute,</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>February 15, 2018</study_first_submitted>
  <study_first_submitted_qc>March 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 20, 2018</study_first_posted>
  <last_update_submitted>December 24, 2019</last_update_submitted>
  <last_update_submitted_qc>December 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hodgkin lymphoma</keyword>
  <keyword>RP6530</keyword>
  <keyword>Pembrolizumab</keyword>
  <keyword>Tenalisib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Tenalisib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

